These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1309 related articles for article (PubMed ID: 31907401)

  • 1. NK cells for cancer immunotherapy.
    Shimasaki N; Jain A; Campana D
    Nat Rev Drug Discov; 2020 Mar; 19(3):200-218. PubMed ID: 31907401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.
    Islam R; Pupovac A; Evtimov V; Boyd N; Shu R; Boyd R; Trounson A
    Cells; 2021 Apr; 10(5):. PubMed ID: 33946954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.
    Childs RW; Carlsten M
    Nat Rev Drug Discov; 2015 Jul; 14(7):487-98. PubMed ID: 26000725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New directions in natural killer cell-based immunotherapy of human cancer.
    Farag SS; Fehniger TA; Becknell B; Blaser BW; Caligiuri MA
    Expert Opin Biol Ther; 2003 Apr; 3(2):237-50. PubMed ID: 12662139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
    Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
    Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded and armed natural killer cells for cancer treatment.
    Shimasaki N; Coustan-Smith E; Kamiya T; Campana D
    Cytotherapy; 2016 Nov; 18(11):1422-1434. PubMed ID: 27497701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
    Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
    Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
    Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
    Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving natural killer cell cancer immunotherapy.
    Berrien-Elliott MM; Romee R; Fehniger TA
    Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review.
    Phung CD; Tran TH; Kim JO
    Arch Pharm Res; 2020 Jan; 43(1):32-45. PubMed ID: 31993969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cancer-natural killer cell immunity cycle.
    Huntington ND; Cursons J; Rautela J
    Nat Rev Cancer; 2020 Aug; 20(8):437-454. PubMed ID: 32581320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell engineering - a new hope for cancer immunotherapy.
    Lin CY; Gobius I; Souza-Fonseca-Guimaraes F
    Semin Hematol; 2020 Oct; 57(4):194-200. PubMed ID: 33256912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
    Smits NC; Coupet TA; Godbersen C; Sentman CL
    Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
    Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
    BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
    Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
    Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.
    Sanchez-Correa B; Lopez-Sejas N; Duran E; Labella F; Alonso C; Solana R; Tarazona R
    Cancer Immunol Immunother; 2019 May; 68(5):861-870. PubMed ID: 30953117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.